

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM852067

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Perceptive Credit Holding III, LP		07/28/2023	Limited Partnership: DELAWARE
RECEIVING PARTY DATA			
Name:	C4 Therapeutics, Inc.		
Street Address:	490 Arsenal Way, Suite 120		
City:	Watertown		
State/Country:	MASSACHUSETTS		
Postal Code:	02472		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	5312039	C4 THERAPEUTICS	
Registration Number:	5933788	DAEDALUS	
Registration Number:	6000314	DAEDALUS	
Serial Number:	88414984		
Serial Number:	87191939	SMART-CAR	
Serial Number:	87428289	C4 PHARMA	
Serial Number:	87428322	C4 PHARMACEUTICALS	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	678-941-0190		
Email:	bbellows@kipsllc.com		
Correspondent Name:	Brent Rexford Bellows		
Address Line 1:	400 Perimter Center Terrace NE Suite 200		
Address Line 4:	Atlanta, GEORGIA 30346		
NAME OF SUBMITTER:	Brent R. Bellows		
SIGNATURE:	/Brent R. Bellows/		
DATE SIGNED:	11/08/2023		

OP \$190.00 5312039

Total Attachments: 11

source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page1.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page2.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page3.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page4.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page5.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page6.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page7.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page8.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page9.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page10.tif
source=4-Perceptive-C4T - ReleaseofSecurityInterestw ExhA&B_FE#page11.tif

RELEASE OF SECURITY INTERESTS IN PATENTS AND TRADEMARKS

THIS RELEASE OF SECURITY INTERESTS IN PATENTS AND TRADEMARKS (this “Release”) dated as of July 28, 2023 is executed by PERCEPTIVE CREDIT HOLDINGS III, LP, as administrative agent for the Secured Parties (in such capacity, the “Administrative Agent”), in favor of C4 THERAPEUTICS, INC., a Delaware corporation (the “Grantor”).

RECITALS

A. WHEREAS, pursuant to that certain Patent and Trademark Security Agreement dated as of June 5, 2020 made by Grantor in favor of Administrative Agent (the “Patent and Trademark Security Agreement”), the Grantor has granted to Administrative Agent a security interest in and to all of the Grantor’s right, title and interest in and to certain trade names, trademarks, and service marks, logos, trademark and service mark registrations, and applications for trademark and service mark registrations, including, but not limited to, those trademarks listed on Exhibit A attached hereto;

B. WHEREAS, pursuant to the Patent and Trademark Security Agreement, the Grantor has granted to Administrative Agent a security interest in and to all of the Grantor’s right, title and interest in and to certain patents and patent applications, including, but not limited to, those patents listed on Exhibit B attached hereto (collectively, with the trademarks referenced in the Patent and Trademark Security Agreement, the “Released Collateral”);

C. WHEREAS, the Patent and Trademark Security Agreement was recorded in the United States Patent and Trademark Office (the “USPTO”) on June 9, 2020, at Reel 6956, Frame 0436, with respect to the trademarks listed on Exhibit A attached hereto;

D. WHEREAS, the Patent and Trademark Security Agreement was recorded in the USPTO on June 9, 2020, at Reel 052874, Frame 0768, with respect to the patents listed on Exhibit B attached hereto;

E. WHEREAS, Administrative Agent wishes to terminate and release, without representation or warranty, its security interest in and to the Released Collateral as provided in this Release.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Administrative Agent hereby terminates the Patent and Trademark Security Agreement, and terminates and releases, without representation or warranty, its security interest in and to the Released Collateral, including all of Grantor’s right, title, and interest in, to and under all of the following:

(i) all of the trade names, trademarks and service marks, logos, trademark and service mark registrations, and applications for trademark and service mark registrations, whether now owned by Grantor or at any time hereafter acquired by Grantor and whether now existing or hereafter coming into existence, that are registered with, or for which applications for registration have been filed with, the United States Patent and Trademark Office, including the trademarks

listed on Exhibit A hereto, and all renewals of trademark and service mark registrations and all goodwill associated therewith; and

(ii) all patents and patent applications, including the inventions and improvements described and claimed therein, in each case whether now owned by Grantor or hereafter acquired by Grantor and whether now existing or hereafter coming into existence, including without limitation those listed on Exhibit B hereto, and all related reissues, divisions, continuations, renewals, extensions and continuations in part thereof; and


Administrative Agent acknowledges that this Release may be filed along with any other necessary documentation with the USPTO or any other governmental office to evidence the release granted herein at the sole expense of the Grantor. Administrative Agent authorizes the Grantor to record this Release with the USPTO and other applicable registry at the sole expense of the Grantor and agrees to provide the Grantor with any information and additional authorization necessary to effect the release of the security interest in the Released Collateral.

[Signature page follows]

IN WITNESS WHEREOF, Administrative Agent has executed this Release of Security Interests in Patents and Trademarks as of the date first set forth above.

PERCEPTIVE CREDIT HOLDINGS III, LP

By: Perceptive Credit Opportunities GP, LLC,
its general partner

DocuSigned by:

By: 79E9FAAB029047C...
Name: Sandeep Dixit
Title: Chief Credit Officer



DocuSigned by:

By: 22AB09C447E748E...
Name: Sam Chawla
Title: Portfolio Manager

EXHIBIT A
TRADEMARKS












US

<u>Owner</u>	<u>Trademarks</u>	<u>Application Number</u>	<u>Filing Date</u>	<u>Status</u>	<u>Registration No.</u>	<u>Registration Date</u>
C4 Therapeutics, Inc.	C4 THERAPEUTICS	86824725	November 18, 2015	Registered	5312039	October 17, 2017
C4 Therapeutics, Inc.	DAEDALUS	88210756	November 29, 2018	Registered	5933788	December 10, 2019
C4 Therapeutics, Inc.		88414911	May 3, 2019	Registered	6000314	March 3, 2020
C4 Therapeutics, Inc.	SMART-CAR (BLOCK)	87191939	October 4, 2016	Pending		
C4 Therapeutics, Inc.	C4 PHARMA	87428289	April 27, 2018	Pending		
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	87428322	April 27, 2018	Pending		

Foreign

<u>Owner</u>	<u>Trademarks</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>	<u>Registration No.</u>
C4 Therapeutics, Inc.	SMART-CAR	Australia	July 18, 2017	Registered	1858824
C4 Therapeutics, Inc.	SMART-CAR	China (People's Republic)	March 28, 2017	Registered	1355736
C4 Therapeutics, Inc.	SMART-CAR	European Union (Community)	March 28, 2017	Registered	1355736
C4 Therapeutics, Inc.	SMART-CAR	Int'l Registration - Madrid Protocol Only	March 28, 2017	Registered	1355736
C4 Therapeutics, Inc.	SMART-CAR	Israel	March 28, 2017	Registered	1355736

<u>Owner</u>	<u>Trademarks</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>	<u>Registration No.</u>
C4 Therapeutics, Inc.	SMART-CAR	Japan	March 28, 2017	Registered	1355736
C4 Therapeutics, Inc.	C4 THERAPEUTICS	Australia	November 22, 2016	Registered	1817411
C4 Therapeutics, Inc.	C4 THERAPEUTICS	Canada	December 1, 2016	Registered	TMA1027514
C4 Therapeutics, Inc.	C4 THERAPEUTICS	European Union (Community)	November 22, 2016	Registered	1325152
C4 Therapeutics, Inc.	C4 THERAPEUTICS	Int'l Registration - Madrid Protocol Only	November 22, 2016	Registered	1325152
C4 Therapeutics, Inc.	C4 THERAPEUTICS	Japan	November 22, 2016	Registered	1325152
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	Australia	October 19, 2017	Registered	1919521
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	Canada	October 23, 2017	Registered	TMA1027570
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	European Union (Community)	October 19, 2017	Registered	1397389
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	Int'l Registration - Madrid Protocol Only	October 19, 2017	Registered	1397389
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	Japan	October 19, 2017	Registered	1397389
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	Australia	October 19, 2017	Registered	1397389
C4 Therapeutics, Inc.	C4 PHARMACEUTICALS	Canada	May 14, 2019	Registered	2015640
C4 Therapeutics, Inc.	DAEDALUS	China (People's Republic)	May 14, 2019	Pending Designation	
C4 Therapeutics, Inc.	DAEDALUS	European Union (Community)	May 14, 2019	Registered	1471566
C4 Therapeutics, Inc.	DAEDALUS	Int'l Registration - Madrid Protocol Only	May 14, 2019	Registered	1471566
C4 Therapeutics, Inc.	DAEDALUS	Israel	May 14, 2019	Registered	1471566
C4 Therapeutics, Inc.	DAEDALUS	Japan	May 14, 2019	Pending Designation	
C4 Therapeutics, Inc.	DAEDALUS	Korea, Republic of	May 14, 2019	Registered	1471566

<u>Owner</u>	<u>Trademarks</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>	<u>Registration No.</u>
C4 Therapeutics, Inc.	 Daedalus	Australia	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	Canada	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	China (People's Republic)	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	European Union (Community)	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	Int'l Registration -Madrid Protocol Only	November 4, 2019	Registered	1508612
C4 Therapeutics, Inc.	 Daedalus	Israel	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	Japan	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	Korea, Republic of	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	Australia	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	Canada	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.	 Daedalus	China (People's Republic)	November 4, 2019	Registered	1508436






<u>Owner</u>	<u>Trademarks</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>	<u>Registration No.</u>
C4 Therapeutics, Inc.		European Union (Community)	November 4, 2019	Published Designation	
C4 Therapeutics, Inc.		Intl Registration - Madrid Protocol Only	November 4, 2019	Registered	1508436
C4 Therapeutics, Inc.		Israel	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.		Japan	November 4, 2019	Pending Designation	
C4 Therapeutics, Inc.		Korea, Republic of	November 4, 2019	Pending Designation	

Exhibit B

PATENTS

US

<u>Owner</u>	<u>Patent Application Number</u>	<u>Filing Date</u>	<u>Patent or Publication Number</u>	<u>Publication Date</u>	<u>Status</u>
C4 Therapeutics, Inc.	16/186333	May 10, 2017	2019-0076539	March 14, 2019	Published
C4 Therapeutics, Inc.	16/186334	May 10, 2017	10,660,968	May 26, 2020	Issued
C4 Therapeutics, Inc.	16/186339	-May 10, 2017	10,646,575	May 12, 2020	Issued
C4 Therapeutics, Inc.	16/186341	May 10, 2017	2019-0076542	March 14, 2019	Published
C4 Therapeutics, Inc.	16/721650	June 20, 2018	2020-0140456A1	May 7, 2020	Published
C4 Therapeutics, Inc.	62/334338	May 10, 2016			Converted
C4 Therapeutics, Inc.	62/334130	May 10, 2016			Converted
C4 Therapeutics, Inc.	62/334395	May 10, 2016			Converted
C4 Therapeutics, Inc.	62/334362	May 10, 2016			Converted
C4 Therapeutics, Inc.	62/522541	June 20, 2017			Converted
C4 Therapeutics, Inc.	62/587303	November 16, 2017			Converted
C4 Therapeutics, Inc.	62/648238	March 26, 2018			Converted
C4 Therapeutics, Inc.	62/726667	September 4, 2018			Converted
C4 Therapeutics, Inc.	62/779319	December 13, 2018			Converted
C4 Therapeutics, Inc.	62/783004	December 20, 2018			Converted
C4 Therapeutics, Inc.	16/809325	September 3, 2018			Filed
C4 Therapeutics, Inc.	16/809336	September 3, 2018			Filed
C4 Therapeutics, Inc.	16/809345	September 3, 2018			Filed
C4 Therapeutics, Inc.	62/814706	March 6, 2019			Converted
C4 Therapeutics, Inc.	62/833107	April 12, 2019			Converted
C4 Therapeutics, Inc.	62/985774	March 5, 2020			Filed
C4 Therapeutics, Inc.	16/872225	May 10, 2017			Filed
C4 Therapeutics, Inc.	16/874475	November 16, 2018			Filed

<u>Owner</u>	<u>Patent Application Number</u>	<u>Filing Date</u>	<u>Patent or Publication Number</u>	<u>Publication Date</u>	<u>Status</u>
C4 Therapeutics, Inc.	16/882236	10-May-17			Filed

Foreign

<u>Owner</u>	<u>Country/Jurisdiction</u>	<u>Patent Application Number</u>	<u>Filing Date</u>	<u>Status</u>
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US17/032046	May 10, 2017	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US17/032031	May 10, 2017	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US17/032051	May 10, 2017	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US17/032041	May 10, 2017	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US18/038534	June 20, 2018	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US18/061573	November 16, 2018	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US19/024094	March 26, 2019	Published
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US19/049582	September 4, 2019	Published
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US19/068045	December 20, 2019	Filed

<u>Owner</u>	<u>Country/Jurisdiction</u>	<u>Patent Application Number</u>	<u>Filing Date</u>	<u>Status</u>
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/EP18/073584	September 3, 2018	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/EP18/073578	September 3, 2018	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/EP18/073555	September 3, 2018	Published and Entered National Stage
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US19/027747	April 16, 2019	Published
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US19/035223	June 3, 2019	Published
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US/021491	March 6, 2020	Filed
C4 Therapeutics, Inc.	Patent Cooperation Treaty	PCT/US20/027678	April 10, 2020	Filed
C4 Therapeutics, Inc.	China	201780036136.X	May 10, 2017	Published
C4 Therapeutics, Inc.	China	201780038257.8	May 10, 2017	Published
C4 Therapeutics, Inc.	China	201780042416.1	May 10, 2017	Published
C4 Therapeutics, Inc.	China	201780040458.1	May 10, 2017	Published
C4 Therapeutics, Inc.	China	201880041214.X	June 20, 2018	Published
C4 Therapeutics, Inc.	China	201880074388.6	November 16, 2018	Filed
C4 Therapeutics, Inc.	China	201880071501.5	September 3, 2018	Filed
C4 Therapeutics, Inc.	China	201880069719.7	September 3, 2018	Filed
C4 Therapeutics, Inc.	China	201880069759.1	September 3, 2018	Filed
C4 Therapeutics, Inc.	European Patent Office	17796812.0	May 10, 2017	Published
C4 Therapeutics, Inc.	European Patent Office	17796880.5	May 10, 2017	Published
C4 Therapeutics, Inc.	European Patent Office	17796814.6	May 10, 2017	Published
C4 Therapeutics, Inc.	European Patent Office	17796809.6	May 10, 2017	Published
C4 Therapeutics, Inc.	European Patent Office	18821251.8	June 20, 2018	Filed
C4 Therapeutics, Inc.	European Patent Office	17189228.4	September 4, 2017	Converted
C4 Therapeutics, Inc.	European Patent Office	18762093.5	September 3, 2018	Filed
C4 Therapeutics, Inc.	European Patent Office	17189231.8	September 4, 2017	Converted
C4 Therapeutics, Inc.	European Patent Office	18762092.7	September 3, 2018	Filed

<u>Owner</u>	<u>Country/Jurisdiction</u>	<u>Patent Application Number</u>	<u>Filing Date</u>	<u>Status</u>
C4 Therapeutics, Inc.	European Patent Office	17189229.2	September 4, 2017	Converted
C4 Therapeutics, Inc.	European Patent Office	18762840.9	September 3, 2018	Filed
C4 Therapeutics, Inc.	European Patent Office	18167561.2	April 16, 2018	Converted
C4 Therapeutics, Inc.	European Patent Office	18168269.1	April 19, 2018	Converted
C4 Therapeutics, Inc.	European Patent Office	18175701.4	June 4, 2018	Converted
C4 Therapeutics, Inc.	Hong Kong	19128326.6	May 10, 2017	Registered
C4 Therapeutics, Inc.	Hong Kong	19128322.5	May 10, 2017	Registered
C4 Therapeutics, Inc.	Hong Kong	19128323.3	May 10, 2017	Registered
C4 Therapeutics, Inc.	Hong Kong	19128403.3	May 10, 2017	Registered

TRADEMARK

REEL: 008253 FRAME: 0744

Exhibit B-4

RECORDED: 11/08/2023